Insight Molecular Diagnostics financials
$3.38+6.29%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 |
|---|---|---|---|---|---|
| Revenue | $239.0K | $32.0K | $1.1M | $260.0K | $518.0K |
| Gross profit | $157.0K | $15.0K | $496.0K | $139.0K | $338.0K |
| Gross margin | 65.7% | 46.9% | 43.5% | 53.5% | 65.3% |
| Operating income | -$11.4M | -$10.3M | -$23.4M | -$11.0M | -$9.8M |
| Net income | -$11.3M | -$4.3M | -$23.0M | -$10.9M | -$9.7M |
| Net margin | −4711.3% | −13406.3% | −2015.4% | −4174.6% | −1880.7% |
| Diluted EPS | $-0.31 | $-0.12 | $-0.71 | $-0.34 | $-0.30 |
| EBITDA | -$10.7M | -$9.7M | -$8.3M | -$10.5M | -$9.3M |
| Operating cash flow | -$9.3M | -$7.6M | -$5.5M | -$4.5M | -$6.2M |
| Free cash flow | -$10.0M | -$8.3M | -$7.0M | -$5.6M | -$6.5M |
| Diluted shares | 36.8M | 34.5M | 32.2M | 32.0M | 32.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 |
|---|---|---|---|---|---|
| Cash & equivalents | $17.8M | $28.2M | $11.6M | $18.7M | $24.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $29.4M | $40.4M | $25.8M | $43.9M | $50.5M |
| Total liabilities | $50.7M | $51.1M | $57.2M | $53.1M | $49.4M |
| Shareholders' equity | -$21.3M | -$10.7M | -$31.5M | -$9.2M | $1.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology